All Search Results
News Releases
Feb 11, 2026, 16:01 ET Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
a landmark narrative review on FDA-approved vesicular monoamine transporter 2 (VMAT2) inhibitors demonstrating the unique profile of INGREZZA in CNS Spectrums. The review highlighted the distinct profile of INGREZZA, including selective VMAT2 targeting, simplified dosing without required titration
More news about: Neurocrine Biosciences, Inc.
Feb 10, 2026, 10:00 ET SkyGrid and Port San Antonio Partner to Enable Advanced Air Mobility at a Joint-Use Airfield
awareness Advanced Air Mobility service provisions Airport and vertiport operational concepts Communication, navigation, and surveillance (CNS) systems and cyber-resilient infrastructure Ground system certification and operational approvals The collaboration will also explore
More news about: SkyGrid
Feb 10, 2026, 08:30 ET Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
looking to refresh aging CNS pipelines. A single successful NSA platform can support multiple indications, creating built-in expansion opportunities and upside optionality. As mental health remains a top global healthcare priority and capital continues flowing into differentiated CNS assets, NSAs are increasingly
More news about: Market News Updates
Feb 10, 2026, 08:00 ET Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.
products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi's research and development currently target two therapeutic areas: infectious diseases and pain/CNS disorders. For more information on Shionogi & Co., Ltd., please
More news about: Cumulus Neuroscience
Feb 10, 2026, 08:00 ET Stellaromics Appoints Industry Veterans Stacie Weninger and Steve McPhail to Board of Directors
application. With more than 20 years of experience building and advising neuroscience companies, her unique understanding of central nervous system (CNS) disorders, and their nuances, will be invaluable as Stellaromics addresses the most challenging questions in disease pathology.Steve McPhail
More news about: Stellaromics